SIS
FDMT icon

Sound Income Strategies’s 4D Molecular Therapeutics FDMT Stock Holding History

Sound Income Strategies’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25
Closed -$247 – 1095
2026
Q1 		$247 Hold
25
– – ﹤0.01% 2457
2025
Q4 		$189 Buy
+25
New +$254 ﹤0.01% 2434

Other funds holding FDMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Sound Income Strategies's FDMT Position: Q2 2026 in Review

Sound Income Strategies sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 25 shares — an estimated $247 sold.

Sound Income Strategies first reported a position in FDMT in Q4 2025 and held it in 2 quarters. The position peaked at $247 in Q1 2026. 73 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Sound Income Strategies reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Sound Income Strategies sold 25 4D Molecular Therapeutics shares in Q2 2026, an estimated $247.
  • Sound Income Strategies first reported a position in 4D Molecular Therapeutics in Q4 2025 and held it in 2 quarters.
  • Sound Income Strategies's 4D Molecular Therapeutics position peaked at $247 in Q1 2026.
  • 73 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.